Clinical trial
A Dose Block-randomized, Double-blind, Placebo-controlled and Dose-escalation Phase I Clinical Trial to Evaluate Safety of BLS-M22 Following Single/Multiple Oral Administration in Healthy Adult Volunteers
NCT03789734 is registered in ClinicalTrials.gov with BioLeaders Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Dose Block-randomized, Double-blind, Placebo-controlled and Dose-escalation Phase I Clinical Trial to Evaluate Safety of BLS-M22 Following Single/Multiple Oral Administration in Healthy Adult Volunteers
- Lead sponsor
- BioLeaders Corporation
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 4, 2019
- Completion date
- November 27, 2020
- Enrollment
- 37 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.